Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Gross Margin (2021 - 2023)

Historic Gross Margin for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to 5.26%.

  • ADC Therapeutics' Gross Margin fell 930400.0% to 5.26% in Q3 2023 from the same period last year, while for Sep 2023 it was 99.26%, marking a year-over-year decrease of 121382800.0%. This contributed to the annual value of 2181331.87% for FY2022, which is 22672789900.0% down from last year.
  • Latest data reveals that ADC Therapeutics reported Gross Margin of 5.26% as of Q3 2023, which was down 930400.0% from 25.03% recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Gross Margin ranged from a high of 99.3% in Q4 2022 and a low of 3818261.6% during Q3 2021
  • Its 3-year average for Gross Margin is 424183.81%, with a median of 96.78% in 2021.
  • As far as peak fluctuations go, ADC Therapeutics' Gross Margin soared by 2000000000bps in 2022, and later tumbled by -930400bps in 2023.
  • Over the past 3 years, ADC Therapeutics' Gross Margin (Quarter) stood at 3818261.6% in 2021, then soared by 100bps to 99.3% in 2022, then crashed by -95bps to 5.26% in 2023.
  • Its last three reported values are 5.26% in Q3 2023, 25.03% for Q2 2023, and 96.89% during Q1 2023.